Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

antibiotic/diarrhea

リンクがクリップボードに保存されます
ページ 1 から 41 結果

Treatment of antibiotic associated diarrhea

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC). More specifically, the invention concerns neutralization of C. difficile toxin A associated with
TECHNICAL FIELD This invention relates to the treatment or prophylaxis of conditions resulting from the accumulation of acid in the gastrointestinal tract of a human or an animal, said accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of the human or animal.

Method of using IL-11 for treating antibiotic induced diarrhea

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF INVENTION The present invention relates generally to methods of treating disorders such as AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer

Method and formula for the prevention of diarrhea

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
TECHNICAL FIELD The present invention relates generally to a method of preventing diarrhea associated with infectious agents such as rotavirus, or diarrhea associated with antibiotic therapies. More specifically, this invention relates to a powdered infant nutritional that contains the probiotic

Methods of treating traveler's diarrhea and hepatic encephalopathy

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

Methods of treating traveler's diarrhea and hepatic encephalopathy

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

Methods of treating traveler's diarrhea and hepatic encephalopathy

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Hepatic encephalopathy (HE) is caused by a reversible decrease in neurologic function associated with liver failure and portosystemic venous shunting. HE occurs in 1 of every 3 cases of cirrhosis, in cases of fulminant hepatic failure reported in the United States (US), and is present in

Compounds and methods for the treatment of bacterial dysentery using antibiotics and toxin binding oligosaccharide compositions

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND OF THE INVENTION Field of the Invention This invention relates to the treatment of diarrhea and related conditions caused by pathogenic E. coli infection. More specifically, this invention is drawn to the unexpected discovery that by administering a composition which binds and removes the

Lactic bacteria and their use in the prevention of diarrhea

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION The present invention relates to the use of lactic bacteria strains in the prevention of diarrhea. More particularly, the present invention concerns the use of lactic bacteria in order to prevent antibiotic associated diarrhea (AAD). DESCRIPTION OF PRIOR ART Diarrhea may be

Herbaceous selenium-enriched SOD non-antibiotic feed and method of manufacture thereof

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF INVENTION The invention belongs to the field of animal and poultry feeds, and in particular, relates to non-antibiotic feeds. BACKGROUND China has the largest capacity in the world in poultry meat production. 71% of all poultry meat consumed in China is chicken. With concepts of food

5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION The present invention relates to 5-ASA derivatives and methods of treating diseases therewith. BACKGROUND OF THE INVENTION Many people suffer from inflammatory bowel disease (IBD). TRD is a generic term used to refer to two inflammatory diseases, ulcerative colitis and Crohn's

Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION The present invention relates to the development of platform technology for targeted, controlled delivery of oral enhanced probiotics for various indications, including for example the active and prophylaxis treatment of Clostridium difficile Infection as well as Metabolic

Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION The present invention relates to the development of platform technology for targeted, controlled delivery of oral enhanced probiotics for various indications, including for example the active and prophylaxis treatment of Clostridium difficile Infection as well as Metabolic

Oral rehydration solution containing indigestible oligosaccharides

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION This invention relates to an oral rehydration solution containing indigestible oligosaccharides for the inhibition of disease states associated with Clostridium difficile. BACKGROUND OF INVENTION The successful management of acute diarrhea is still a challenge today. Acute

Inhibition of C. difficile infections by indigestible oligosaccharides

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
FIELD OF THE INVENTION This invention relates to the use of indigestible oligosaccharides in the inhibition of disease states by Clostridium difficile. BACKGROUND OF INVENTION Clostridium difficile (C. difficile) is the leading known cause of nosocomial infections. Greenough et al., "Diarrhea in the
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge